Management of radiation-induced nausea and vomiting

Management of radiation-induced nausea and vomiting (RINV) includes both prevention and therapy. Primary prevention involves implementation of measures to modify risk factors. Secondary prevention involves prophylaxis and treatment with 5HT3 receptor antagonists (5HT3 RAs) with or without corticoste...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology 2007-04, Vol.35 (4), p.34-36
Main Author: Abdelsayed, George G
Format: Article
Language:English
Subjects:
Advanced Basic Science
Antiemetics - therapeutic use
Hematology, Oncology and Palliative Medicine
Humans
Nausea - drug therapy
Nausea - etiology
Nausea - prevention & control
Radiation Injuries - drug therapy
Radiation Injuries - etiology
Radiation Injuries - prevention & control
Radioactive Hazard Release
Radiotherapy - adverse effects
Serotonin 5-HT3 Receptor Antagonists
Vomiting - drug therapy
Vomiting - etiology
Vomiting - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of radiation-induced nausea and vomiting (RINV) includes both prevention and therapy. Primary prevention involves implementation of measures to modify risk factors. Secondary prevention involves prophylaxis and treatment with 5HT3 receptor antagonists (5HT3 RAs) with or without corticosteroids, dopamine antagonists, antihistamines, or anticholinergics. 5HT3 RAs are also useful in treatment of RINV with significantly better outcomes, compared to other antiemetics or placebo. Agents include ondansetron, granisetron, dolasetron, palonosetron, and tropisitron. These agents may be useful in both the radiotherapy patient and the individual who has been accidentally exposed to ionizing radiation.
ISSN:0301-472X
1873-2399
DOI:10.1016/j.exphem.2007.01.010